The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 19, 2016
Filed:
Apr. 03, 2014
Pfizer Inc., New York, NY (US);
Amgen Fremont Inc., Thousand Oaks, CA (US);
Ronald P. Gladue, Stonington, CT (US);
Bradley T. Keller, Chesterfield, MO (US);
Shinji Ogawa, Chesterfield, MO (US);
Arvind Rajpal, San Francisco, CA (US);
Laurie A. Tylaska, Preston, CT (US);
Shelley Sims Belouski, Camarillo, CA (US);
Larry L. Green, San Francisco, CA (US);
Meina Liang, Santa Clara, CA (US);
Pfizer Inc., New York, NY (US);
Amgen Fremont Inc., Thousand Oaks, CA (US);
Abstract
Provided are antibodies including human antibodies and antigen-binding portions thereof that specifically bind to CCR2, preferably human CCR2, and that may inhibit CCR2. The present antibodies may bind to the first and/or second extracellular loops of CCR2. Isolated heavy and light chains derived from the antibodies and nucleic acid molecules encoding the antibodies and chains are provided. Methods of making and using the anti-CCR2 antibodies or antigen-binding portions, and compositions comprising these antibodies or antigen-binding portions, including compositions for diagnosis and treatment, are provided. Also provided are gene therapy methods using nucleic acid molecules encoding the heavy and/or light chains that comprise the human anti-CCR2 antibodies or antigen-binding portions thereof.